Last reviewed · How we verify
Ovaleap®
At a glance
| Generic name | Ovaleap® |
|---|---|
| Sponsor | Teva Pharma GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Dual Trigger for Elective Fertility Preservation (PHASE4)
- A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovaleap® CI brief — competitive landscape report
- Ovaleap® updates RSS · CI watch RSS
- Teva Pharma GmbH portfolio CI